A Stage 1 trial with ABT-806.

Abbott initiates ABT-806 Phase 1 trial in EGFR expressing tumors Life Technology Pharmaceuticals announced today a milestone linked to monoclonal-antibody 806 licensed to Abbott cyclobenzaprine . A Stage 1 trial with ABT-806, a humanized version of mAb 806 that selectively targets the epidermal growth factor receptor , has been initiated by Abbott in the U.S. The trial will assess the basic safety and pharmacokinetics of ABT-806 in patients with advanced solid tumors likely or known to express EGFR. A clinical research of the chimeric predecessor mAb, ch806, published in PNAS, suggested an ability to focus on and bind selectively to EGFR expressing tumors, with no targeting of normal tissues essentially.

Parkinson’s disease is usually a movement disorder caused by progressive neurodegeneration of specific brain areas. This is referred to as off period. Within an interim evaluation of the long-term research, data were analyzed from 192 individuals with advanced Parkinson’s disease who experienced finished 12 weeks of treatment with LCIG for 16 hours each day.9 fewer hours of off time and 4.6 extra hours of on time without troublesome dyskinesias.5 %) and appeared to be largely related to the surgical procedure.7 %), complications of device insertion and procedural discomfort .6 %) and pneumoperitoneum .3 %) withdrew due to a detrimental event.